Weber said it is the right time to appoint a successor, given the company's "competitive growth outlook, new product launches expected from the second half of 2026 onwards, and the anticipated ...

Allogeneic stem cell therapy allows "off the shelf" cells ... In the likely event of an EU licence for the therapy, Takeda will pay a 15 million euro fee to Tigenix. Apart from affecting the ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Japan’s market growth accelerates through dynamic clinical partnerships, biologic breakthroughs, and automated facilities. Japanese firms confront shifting priorities in specialized therapies, ...

The list of 36 drugs, which are exempt from basic customs duty, includes many expensive and imported medicines that can ...

SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 27, 2025 / ClearPoint Neuro, Inc. (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the ...

Plasma-derived therapies are essential for treating a wide range of conditions, including immune deficiencies, bleeding ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. The company called the ...